CVS Health Corp (CVS)vsRLX Technology Inc (RLX)
CVS
CVS Health Corp
$95.93
+1.17%
HEALTHCARE · Cap: $128.46B
RLX
RLX Technology Inc
$2.00
-0.99%
CONSUMER DEFENSIVE · Cap: $2.51B
Smart Verdict
WallStSmart Research — data-driven comparison
CVS Health Corp generates 9164% more annual revenue ($405.62B vs $4.38B). RLX leads profitability with a 22.5% profit margin vs 0.7%. RLX trades at a lower P/E of 18.6x. RLX earns a higher WallStSmart Score of 68/100 (B-).
CVS
Buy65
out of 100
Grade: C+
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.3%
Fair Value
$140.72
Current Price
$95.93
$44.79 discount
Intrinsic value data unavailable for RLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 63.1% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 3.4B in free cash flow
Reasonable price relative to book value
Revenue surging 107.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 23 of every $100 in revenue as profit
Earnings expanding 27.1% YoY
Areas to Watch
ROE of 3.8% — below average capital efficiency
0.7% margin — thin
Operating margin of 4.1%
Elevated debt levels
ROE of 6.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CVS
The strongest argument for CVS centers on PEG Ratio, EPS Growth, Market Cap. PEG of 0.28 suggests the stock is reasonably priced for its growth.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, Debt/Equity. Profitability is solid with margins at 22.5% and operating margin at 16.7%. Revenue growth of 107.4% demonstrates continued momentum.
Bear Case : CVS
The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 44.2x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
CVS profiles as a value stock while RLX is a growth play — different risk/reward profiles.
RLX carries more volatility with a beta of 1.14 — expect wider price swings.
RLX is growing revenue faster at 107.4% — sustainability is the question.
CVS generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
RLX scores higher overall (68/100 vs 65/100), backed by strong 22.5% margins and 107.4% revenue growth. CVS offers better value entry with a 45.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVS Health Corp
HEALTHCARE · HEALTHCARE PLANS · USA
CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.
Visit Website →RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other HEALTHCARE PLANS Stocks
Want to dig deeper into these stocks?